Novo Nordisk A/S (NYSE:NVO) Shares Sold by Net Worth Advisory Group

Net Worth Advisory Group reduced its position in Novo Nordisk A/S (NYSE:NVO) by 4.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 5,811 shares of the company’s stock after selling 243 shares during the quarter. Net Worth Advisory Group’s holdings in Novo Nordisk A/S were worth $500,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of NVO. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at $42,000. Mesirow Financial Investment Management Inc. increased its stake in Novo Nordisk A/S by 7.0% in the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 11,610 shares of the company’s stock valued at $1,382,000 after buying an additional 763 shares during the period. Crossmark Global Holdings Inc. increased its stake in Novo Nordisk A/S by 31.3% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 52,596 shares of the company’s stock valued at $6,263,000 after buying an additional 12,539 shares during the period. Ashton Thomas Securities LLC boosted its position in shares of Novo Nordisk A/S by 20.8% during the 3rd quarter. Ashton Thomas Securities LLC now owns 11,024 shares of the company’s stock worth $1,313,000 after purchasing an additional 1,899 shares in the last quarter. Finally, Kennebec Savings Bank purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $106,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. BMO Capital Markets decreased their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $78.87 on Tuesday. Novo Nordisk A/S has a 52 week low of $77.79 and a 52 week high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm’s 50-day simple moving average is $84.77 and its 200 day simple moving average is $104.45. The firm has a market capitalization of $353.91 billion, a PE ratio of 23.97, a P/E/G ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S’s payout ratio is presently 47.72%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.